Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3

Journal of Clinical Oncology

Volumn 28, Issue 28, 2010, Pages 4339-4345

  Fischer, Thomas ^a   Stone, Richard M ^a   DeAngelo, Daniel J ^a   Galinsky, Ilene ^a   Estey, Elihu ^a   Lanza, Carlo ^a   Fox, Edward ^a   Ehninger, Gerhard ^a   Feldman, Eric J ^a   Schiller, Gary J ^a   Klimek, Virginia M ^a   Nimer, Stephen D ^a   Gilliland, D Gary ^a   Dutreix, Catherine ^a   Huntsman Labed, Alice ^a   Virkus, Jodi ^a   Giles, Francis J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; MIDOSTAURIN; 4'-N-BENZOYLSTAUROSPORINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PROTEIN TYROSINE KINASE; STAUROSPORINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASTHENIA; BLOOD; BONE MARROW; CANCER GROWTH; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENE MUTATION; HUMAN; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENZYMOLOGY; GENETICS; MUTATION; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; MYELODYSPLASTIC SYNDROMES; RECEPTOR PROTEIN-TYROSINE KINASES; STAUROSPORINE; TREATMENT OUTCOME;

EID: 78049426367     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.9678     Document Type: Article

References (26)

1. Burnett AK, Goldstone AH, Stevens RM, et al: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial: UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 351:700-708, 1998 (Pubitemid 28105339)
2. Stone RM: The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 52:363-371, 2002
3. Breitenbuecher F, Schnittger S, Grundler R, et al: Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 113:4074-4077, 2009
4. Kayser S, Schlenk RF, Londono MC, et al: Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 114:2386-2392, 2009
5. Gilliland DG, Griffin JD: Role of FLT3 in leukemia. Curr Opin Hematol 9:274-281, 2002 (Pubitemid 34596870)
6. Levis M, Small D: Novel FLT3 tyrosine kinase inhibitors. Expert Opin Investig Drugs 12:1951-1962, 2003
7. Weisberg E, Boulton C, Kelly LM, et al: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1:433-443, 2002 (Pubitemid 41039124)
8. Kelly LM, Yu JC, Boulton CL, et al: CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 1:421-432, 2002 (Pubitemid 41039123)
9. Kelly LM, Liu Q, Kutok JL, et al: FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99:310-318, 2002
10. Pratz KW, Sato T, Murphy KM, et al: FLT3 mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 115:1425-1432, 2009
11. Propper DJ, McDonald AC, Man A, et al: Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19:1485-1492, 2001 (Pubitemid 32202557)
12. Stone RM, DeAngelo DJ, Klimek V, et al: Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105:54-60, 2005 (Pubitemid 40053063)
13. Manley PW, Boulton C, Caravatti G, et al: Preclinical profile of PKC412 (midostaurin) as an FLT3 inhibitor for the therapy of AML. Presented at the American Association for Cancer Research Annual Meeting, Washington, DC, July 11-14, 2003 (poster 1004)
14. Yin O, Wang Y, Lanza C, et al: Pharmacokinetics (PK) and pharmacodynamics (PD) of midostaurin (PKC412) in patients with acute myeloid leukemia (AML). J Clin Oncol 26:388s, 2008 (abstr 7064)
15. Estey EH, Thall PF: New designs for phase 2 clinical trials. Blood 102:442-448, 2003 (Pubitemid 36841959)
16. Thall PF, Estey EH: A bayesian strategy for screening cancer treatments prior to phase II clinical evaluation. Stat Med 12:1197-1211, 1993 (Pubitemid 23220540)
17. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
18. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000
19. Yin OQ, Wang Y, Schran H: A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. Clin Pharmacokinet 47:807-816, 2008
20. Dutreix C, Huntsman Labed A, Roesel J, et al: Midostaurin: Review of pharmacokinetics (PK) and PK/pharmacodynamic (PD) relationship in AML/MDS patients. J Clin Oncol 27, 2009 (abstr e14540)
21. Andreeff M, McQueen T, Williams C, et al: Clonal abnormalities in MSC derived from AML bone marrows. Blood 112, 2008 (abstr 2428)
22. Levis M, Brown P, Smith BD, et al: Plasma inhibitory activity (PIA): A pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 108:3477-3483, 2006
23. Heidel F, Solem FK, Breitenbuecher F, et al: Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of asn-676 in the FLT3 tyrosine kinase domain. Blood 107:293-300, 2006 (Pubitemid 43053554)
24. Bullinger L, Dohner K, Kranz R, et al: An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 111:4490-4495, 2008
25. Levis M, Pham R, Smith BD, et al: In vitro studies of a FLT3 inhibitor combined with chemotherapy: Sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104: 1145-1150, 2004
26. Stone RM, Fischer T, Paquette R, et al: A phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: Overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3. Blood 114, 2009 (abstr 634)